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Table 1
Changes in Scores of the Primary and the Secondary Evaluation Parameters at 6
months post t.
TG-C Placebo P values
IKDC 18.114.3 8.511.0 p<0.01
WOMAC -15.416.7 -6.913.6 p<0.06
KOOS -25.623.6 -14.318.1 p<0.02
VAS -27.325.6 -11.718.0 p<0.05
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S147undergoing metal-on-metal hip resurfacing arthroplasty (MOMHRA).
Currently there is little evidence-based guidance on the rehabilitation
of patients with hip resurfacing. Previous work suggests that there is
frequently persistent muscle weakness and poor functional mobility.
Methods: Single blinded randomised control trial. Setting: Hospital
trust specialising in orthopedic surgery. Participants: 80 patients
undergoing elective hip resurfacing arthroplasty(MOMHRA). Interven-
tion: Physiotherapy exercise programme tailored to hip resurfacing,
delivered in an out-patient setting. Comparison group of standard hip
arthroplasty rehabilitation.
Main Outcomes: Oxford Hip Score (OHS), secondary measures of Hip
disability and Osteoarthritis Outcome Score (HOOS), UCLA activity
score, and EQ 5D. Hip range of motion, hip muscle strength and patient
selected goals were also assessed. Measures were recorded at baseline
and at 6, 16 and 52 weeks after surgery.
Results: Linear regression model, adjusted by baseline OHS, detected
a 5.8 unit change in OHS at 52 weeks when the exposure group moved
from control to treatment (p¼0.001); effect size 0.76. There was
a statistically signiﬁcant increase in HOOS of 12.4 at 52 weeks
(p<0.0005); effect size 0.76 when comparing the treatment and
control groups. The UCLA activity score showed an increase of 0.66
(p¼0.019); effect size 0.43 in favour of the treatment group at 52
weeks. The EQ5D summary index increased by 0.85 (p¼0.005); effect
size 0.76 at 52 weeks when moving from the control group to the
treatment group. Hip ﬂexion (increase of 17.9, p<0.0005) and hip
extension (increase of 5.7, p¼.004) also showed a marked improve-
ment between the treatment group and the control group. Muscle
strength improved more in the intervention group but was not
statistically signiﬁcant. Eighty percent (32 of 40) of the intervention
group fully met their self-selected goal compared to 55% (22 of 40) of
the control group.
Conclusions: A simple tailored exercise programme resulted in marked
increases in hip range of motion and self reported function than the
previous conventional rehabilitation programme. A change in the
emphasis of post-operative rehabilitation could improve outcome for
patients after hip resurfacing arthroplastyĂ273
TISSUEGENE-C (TG-C) IN PATIENTS WITH OSTEOARTHRITIS: A PHASE
IIB CLINICAL STUDY
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Lee, Bumsup Lee. Kolon Life Sci., Seoul, Republic of Korea
Purpose: TG-C is a cell mediated gene therapy that contains non-
transduced (hChonJ) and transduced (hChonJb#7) human allogeneic
chondrocytes. The hChonJb#7 cells were transduced with TGF-b1 gene-
containing retroviral vector.
TG-C has been tested in Phase I and Phase IIa clinical studies in osteo-
arthritis patients and has proved its safety and efﬁcacy in the patients.
Methods: In the current study, the placebo-controlled, randomized,
single blind phase IIb trial was conducted to determine both safety and
efﬁcacy in patients with knee osteoarthritis. Participants (n ¼ 54) with
a conﬁrmed diagnosis of knee osteoarthritis by X-ray and MRI were
randomized into the treatment group (TG-C, 1.8x107cells/knee, n ¼ 27)
and the placebo group (saline, n ¼ 27). The primary evaluation
parameter was International Knee Documentation Committee (IKDC)
which measures pain, sports activities, and daily function. The
secondary evaluation parameters were Western-Ontario and Mac-
Master University (WOMAC) score, Knee Injury and Osteoarthritis
Outcome Score (KOOS), and 100mmVisual Analogue Scale (VAS). These
parameters were assessed at 12 and 24 weeks post treatment. Addi-
tionally, the changes in biomarkers were assessed in serum and urine
samples. Safety measures, including physical exams, complete blood
count, and serum chemistry were included up to 6 months post treat-
ment. Blood samples were screened to detect the replication competent
retrovirus, TGF-b1 DNA and protein starting from 2 weeks up to 6
months post treatment.
Results: TG-C treatment group showed improvement in IKDC, WOMAC,
KOOS and 100 mm VAS scores compared to placebo group as shown in
table 1.
Conclusions: In summary, the current Phase IIb study indicated that
TG-C treatment improved the evaluation criteria for pain, sports
activities, and quality of daily life in patients with knee osteoarthritis
when compared to the placebo group.274
DIFFERENT RECOVERY GROUPS 2 YEARS AFTER TOTAL KNEE
ARTHROPLASTY
D. Logerstedt, J. Zeni, Jr., L. Snyder-Mackler. Univ. of Delaware, Newark,
DE, USA
Purpose: Patients early after total knee arthroplasty (TKA) have
performance-based activity limitations. Performance-based measures
are more responsive to change than patient-reported outcomes; No
studies have investigated clinically signiﬁcant change relative to
return to normal ranges and minimal amount of change. The purpose
of this study was to quantify clinical signiﬁcant change in the Timed
Up and Go (TUG) and Stair Climbing Test (SCT) up to two years after
TKA.
Methods: One hundred twenty-one patients (40% women) started
a progressive quadriceps strengthening program four weeks after TKA.
All patients received 6 weeks of physical therapy. Patients completed
the TUG and SCTafter the intervention (baseline) and one and two years
after TKA. ANOVA was used to determine change over time. Using
healthy age- and sex-based normative data for the TUG and SCT,
patients were classiﬁed into different recovery groups based on the
Jacobsonmethod: “Recovered”-exceed the age- and sex-based cutoff for
knee functionwithin normal ranges at baseline andmaintained this at 2
years, “Improved to Recovered”-exceed the cutoff score at 2 years and
had a reliable change index (RCI) greater than or equal to 1.96 for the
change in Z-scores from baseline to 2 years, “Improved”-RCI was greater
than or equal to 1.96 but they did not exceed the cutoff score,
“Unchanged” -did not exceed the cutoff score and their RCI was
between 1.96 and -1.96, and “Deteriorated” -did not exceed the cutoff
score and their RCI was less than -1.96.
Results: TUG and SCT scores improved over time (p<.001) (Table 1). For
the TUG and SCT, between 34.8-39.7% of patients were classiﬁed as
either “Recovered” or “Improved to Recovered” two years after TKA
(Table 2). However, between 46.8-52.0% did not improve or deterio-
rated two years after TKA (Table 2). Interestingly, for the TUG, the
“Deteriorated” group was stable up to one year but worsened between
one and two years (Figure A). The “Improved” group had signiﬁcant
changes between 3 months and one year and then plateaued (Figure A).
A different pattern was seen for the SCT. The “Deteriorated” times
slowed at each time period, whereas, the “Improved” group times were
faster at each time period (Figure B).
Conclusions: A substantial number of patients had clinically signiﬁcant
improvement or had scores within the healthy range two years after
TKA. However, close to half the patients did not improve or deteriorated
by two years. Factors such as increased BMI or symptoms in the
nonsurgical limb may contribute to the lack of improvement or decline
in function in some individuals.
